Resource Summary Report

Generated by kravitz2 on Jul 31, 2026

SurvComp

RRID:SCR_003054
Type: Tool

Proper Citation

SurvComp (RRID:SCR_003054)

Resource Information

URL: http://www.bioconductor.org/packages/release/bioc/html/survcomp.html

Proper Citation: SurvComp (RRID:SCR_003054)

Description: R package providing functions to assess and to compare the performance of risk prediction (survival) models.

Abbreviations: survcomp

Synonyms: survcomp - Performance Assessment and Comparison for Survival Analysis

Resource Type: software resource

Defining Citation: PMID:21903630

Keywords: differential expression, gene expression, visualization, mac os x, unix/linux, windows, r

Availability: Free, Available for download, Freely available

Resource Name: SurvComp

Resource ID: SCR_003054

Alternate IDs: OMICS_02373

Record Creation Time: 20220129T080216+0000

Record Last Update: 20260725T190537+0000

Ratings and Alerts

No rating or validation information has been found for SurvComp.

No alerts have been found for SurvComp.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 58 mentions in open access literature.

Listed below are recent publications. The full list is available at kravitz2 .

Huang C, et al. (2025) Prediction of recurrence after resection in hepatocellular carcinoma via whole liver deep learning on preoperative contrast-enhanced CT. Scientific reports, 15(1), 42975.

Lee JW, et al. (2025) BRCAGenie: A machine learning-driven 43-gene polygenic risk score model for precision prediction of breast cancer survival. Journal of translational medicine, 23(1), 1191.

Zhao Y, et al. (2025) Artificial intelligence-assisted RNA-binding protein signature for prognostic stratification and therapeutic guidance in breast cancer. Frontiers in immunology, 16, 1583103.

Yang J, et al. (2025) A PANoptosis-Based Signature for Survival and Immune Predication in Glioblastoma Multiforme. Annals of clinical and translational neurology, 12(7), 1334.

Cai D, et al. (2025) Personalized risk stratification in colorectal cancer via PIANOS system. Nature communications, 16(1), 6561.

Lou Q, et al. (2025) Predictive nomogram for severe acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: a multicenter retrospective study. Scientific reports, 15(1), 33279.

Li H, et al. (2024) Proteome-wide Mendelian randomization identifies causal plasma proteins in lung cancer. iScience, 27(2), 108985.

Guo Q, et al. (2024) Heparin-enriched plasma proteome is significantly altered in Alzheimer's Disease. Research square.

Ma L, et al. (2024) Deep learning model based on contrast-enhanced MRI for predicting post-surgical survival in patients with hepatocellular carcinoma. Heliyon, 10(11), e31451.

Li B, et al. (2024) Artificial intelligence-driven prognostic system for conception prediction and management in intrauterine adhesions following hysteroscopic adhesiolysis: a diagnostic study using hysteroscopic images. Frontiers in bioengineering and biotechnology, 12, 1327207.

Lv L, et al. (2024) A Comprehensive Prognostic Model for Colon Adenocarcinoma Depending on Nuclear-Mitochondrial-Related Genes. Technology in cancer research & treatment, 23, 15330338241258570.

Fang XL, et al. (2024) A radiogenomic clinical decision support system to inform individualized treatment in advanced nasopharyngeal carcinoma. iScience, 27(8), 110431.

Guo Q, et al. (2024) Heparin-enriched plasma proteome is significantly altered in Alzheimer's disease. Molecular neurodegeneration, 19(1), 67.

Cai D, et al. (2023) An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer. Cancer medicine, 12(7), 8924.

Saillard C, et al. (2023) Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Nature communications, 14(1), 3459.

Yang C, et al. (2023) Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatology international, 17(1), 237.

Yolchuyeva S, et al. (2023) Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study. JTO clinical and research reports, 4(12), 100602.

Zhai W, et al. (2022) Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. National science review, 9(3), nwab192.

Qiu L, et al. (2022) Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma. Genes & diseases, 9(1), 116.

Liu Y, et al. (2022) Construction of a 10-gene prognostic score model of predicting recurrence for laryngeal cancer. European journal of medical research, 27(1), 249.